Curis gains FDA & EMA support for accelerated approval of emavusertib in PCNSL

CURIS INC

2025-Q1 EPS reported -$1.25 revenue$2,380,000

FDA and EMA agree TakeAim Lymphoma study may support accelerated approval path for PCNSL.
Emavusertib granted Orphan Drug Designation for PCNSL in both US and EU.
In 20 BTKi-experienced PCNSL patients: 6 objective responses, 4 complete responses.
Q4 2024 net loss $9.6M ($1.25/share); FY2024 net loss $43.4M ($6.88/share).
Cash $20.0M at Dec 31, 2024; plus $10M from March 2025 offerings funds ops into Q4 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.